Ballentine Partners LLC Buys Shares of 12,848 Theravance Biopharma, Inc. (NASDAQ:TBPH)

Ballentine Partners LLC purchased a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,848 shares of the biopharmaceutical company’s stock, valued at approximately $104,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. grew its position in Theravance Biopharma by 41.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock valued at $5,005,000 after purchasing an additional 163,951 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after buying an additional 135,426 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Theravance Biopharma in the 2nd quarter valued at about $986,000. Bank of Montreal Can increased its position in shares of Theravance Biopharma by 141.0% in the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after acquiring an additional 93,702 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after acquiring an additional 91,679 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were acquired at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the purchase, the insider now owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. TD Cowen decreased their price objective on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their target price for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $8.47 on Thursday. The stock has a market cap of $411.92 million, a PE ratio of -9.85 and a beta of 0.25. The firm has a 50-day moving average of $8.25 and a 200-day moving average of $8.73. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The firm had revenue of $14.26 million for the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same quarter in the prior year, the firm earned ($0.28) EPS. As a group, analysts predict that Theravance Biopharma, Inc. will post -1.04 EPS for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.